Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.4331
-0.0342 (-7.32%)
At close: May 30, 2025, 4:00 PM
0.4400
+0.0069 (1.59%)
After-hours: May 30, 2025, 7:52 PM EDT
Vaxart Employees
Vaxart had 105 employees as of December 31, 2024. The number of employees decreased by 4 or -3.67% compared to the previous year.
Employees
105
Change (1Y)
-4
Growth (1Y)
-3.67%
Revenue / Employee
$451,381
Profits / Employee
-$553,543
Market Cap
98.72M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VXRT News
- 1 day ago - Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - GlobeNewsWire
- 1 day ago - Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders - GlobeNewsWire
- 2 days ago - Vaxart Answers Additional Frequently Asked Questions from Retail Investors - GlobeNewsWire
- 3 days ago - Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewsWire
- 9 days ago - Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewsWire
- 10 days ago - Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting - GlobeNewsWire
- 15 days ago - Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewsWire